Kappa opioid antagonists: Past successes and future prospects

AAPS Journal

Volumn 7, Issue 3, 2005, Pages

  Metcalf, Matthew D ^a   Coop, Andrew ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Antagonist; Kappa; Opiate; Opioid; Receptor

Indexed keywords

3 [1 (3,4 DICHLORO N METHYLPHENYLACETAMIDO) 2 (1 PYRROLIDINYL)ETHYL]PHENOXYACETIC ACID; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; 5' GUANIDINONALTRINDOLE; 5,9 DIETHYL 2 (3 FURYLMETHYL) 2' HYDROXY 6,7 BENZOMORPHAN; AMIDINE; BENZENE DERIVATIVE; BINALTORPHIMINE; CHLORNALTREXAMINE; CHLORPHENIRAMINE; COCAINE; CYPRODIME; ENADOLINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; GUANIDINENALTRINDOLE DERIVATIVE; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; LIGAND; MORPHINE; NALOXONE; NALTREXAMINE DERIVATIVE; NALTREXONE; NALTRINDOLE; NORBINALTROPHIMINE; NORBINALTROPHIMINE DERIVATIVE; OPIATE ANTAGONIST; QUADAZOCINE; TRIEHYLENEGLYCONALTREXAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; KAPPA OPIATE RECEPTOR; NARCOTIC ANTAGONIST;

BIOCHEMISTRY; COCAINE DEPENDENCE; DEPRESSION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EATING DISORDER; FUTUROLOGY; HUMAN; IC 50; NONHUMAN; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; PHARMACEUTICS;

ANIMALS; HUMANS; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID, KAPPA; TECHNOLOGY, PHARMACEUTICAL;

EID: 33646669747     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070371     Document Type: Review

References (118)

1. Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR. Human mu opiate receptor - cDNA and genomic clones, pharmacologic characterization and chromosomal assignment, FEBS Lett. 1994;338:217-222.
2. Mansson E, Bare L, Yang D. Isolation of a human kappa opioid receptor cDNA from placenta. Biochem Biophys Res Commun. 1994;202:1431-1434.
3. Kieffer BL, Befort K, Gavriaux-Ruff C, Hirth CG. The opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA. 1992:89:12048-12052.
4. Peters GR, Gaylor S. Human central nervous system (CNS) effects of a selective kappa opioid agonist [abstract] Clin Pharmacol Ther. 1989;45:130.
5. Casy AF, Parfitt RT. Opioid Analgesics. New York and London: Plenum Press; 1986.
6. Schmidhammer H. Opioid receptor antagonists. Prog Med Chem. 1998;35:83-132.
7. Coop A, Rice KC. Role of delta-opioid receptors in biological processes. Drug News Perspect. 2000;13:481-487.
8. Rees DC. Chemical structures and biological activities of non-peptide selective kappa opioid ligands. Prog Med Chem. 1992;29:109-139.
9. Kuzmin AV, Gerrits MAFM, Van Ree JM. Kappa-opioid receptor blockade with nor-binaltorphimine modulates cocaine self-administration in drug-naïve rats. Eur J Pharmacol. 1998;358:197-202.
10. Mague SD, Pliakas AM, Todtenkopf MS, et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther. 2003;305:323-330.
11. Jewett DC, Grace MK, Jones RM, Billington CJ, Portoghese PS, Levine AS. The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide-Y-induced feeding in rats. Brain Res. 2001;909:75-80.
12. Roth BL, Baner K, Westkaemper R, et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA. 2002;99:11934-11939.
13. Schmidhammer H. Opioid receptor antagonists. Prog Med Chem. 1998;35:83-132.
14. Bennett MA, Murray TF, Aldrich JV. Identification of arodyn, a novel acetylated dynorphin A-(1-11) analogue, as a κ opioid receptor antagonist. J Med Chem. 2002;45:5617-5619.
15. Weltrowska G, Lu Y, Lemieux C, Chung NN, Schiller PW. A novel cyclic enkephalin analogue with potent opioid antagonist activity. Bioorg Med Chem Lett. 2004;14:4731-4733.
16. Aldrich JV. Analgesics. In: Abraham DJ, ed. Burger's Medicinal Chemistry and Drug Discovery, Volume 6, Nervous System Agents. 6th ed. New York: John Wiley and Sons; 2003:329-482.
17. Cowan A, Lewis JW. Buprenorphine: Combatting Drug Abuse with a Unique Opioid. New York: John Wiley and Sons; 1995.
18. Devi LA. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling, and trafficking. Trends Pharmacol Sci. 2001;22:532-537.
19. Rusovici DE, Negus SS, Mello NK, Bidlack JM. κ-opioid receptors are differentially labeled by arylacetamides and benzomorphans. Eur J Pharmacol. 2004;485:119-125.
20. Zimmerman DM, Leander JD. Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents. J Med Chem. 1990;33:895-902.
21. Larson DL, Jones RM, Hjorth SA, Schwartz TW, Portoghese PS. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists. J Med Chem. 2000;43:1573-1576.
22. Jones RM, Hjorth SA, Schwartz TW, Portoghese PS. Mutational evidence for a common κ antagonist binding pocket in the wild-type κ and mutant μ[K303E] opioid receptors. J Med Chem. 1998;41:4911-4914,
23. Sharma SK, Jones RM, Metzger TG, Ferguson DM, Portoghese PS. Transformation of a κ-opioid receptor antagonist to a κ-agonist by transfer of a guanidinium group form the 5′- to the 6′-position of naltrindole. J Med Chem. 2001;44:2073-2079.
24. Stevens WC, Jones RM, Subramanian G, Metzger TG, Ferguson DM, Portoghese PS. Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J Med Chem, 2000;43:2759-2769.
25. Metzger TG, Paterlini MG, Ferguson DM, Portoghese PS. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site directed mutagenesis of opioid receptors: exploring the 'address' recognition locus. J Med Chem. 2001;44:857-862.
26. Kong H, Raynor K, Yano H, Takeda J, Bell GI, Reisine T. Agonists and antagonists bind to different domanins of the cloned κ opioid receptor. Proc Natl Acad Sci USA. 1994;91:8042-8046.
27. Hjorth SA, Thirstrup K, Grandy DK, Schwartz TW. Analysis of selective binding epitopes for the κ-opioids receptor antagonist nor-binaltorphimine. Mol Pharmacol. 1995;47:1089-1094.
28. Eguchi M. Recent Advances in selective opioid receptor agonists and antagonists. Med Res Rev. 2004;24:182-212.
29. Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective κ-opioid receptor antagonists. Life Sci, 1987;40:1287-1292.
30. Butelman ER, Harris TJ, Kreek MJ. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl). 2004;172:220-224.
31. Erez M, Takemori AE, Portoghese PS. Narcotic antagonistic potency of bivalent ligands which contain β-naltrexamine. Evidence for bridging between proximal recognition sites. J Med Chem. 1982;25:847-849.
32. Portoghese PS, Takemori AE. TENA, a selective kappa opioid receptor antagonist. Life Sci. 1985;36:801-805.
33. Botros S, Lipkowski AW, Takemori AE, Portoghese PS. Investigation of the structural requirements for the κ-selective opioid receptor antagonist, 6β,6β′-[ethlenebis(oxyethyleneimino)]bis[17- (cyclopropylmethyl)-4, 5α-epoxymorphinan-3, 14-diol] (TENA). J Med Chem. 1986;29:874-876.
34. Portoghese PS, Ronsisvalle G, Larson DL, Takemori AE. Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers. J Med Chem. 1986;29:1650-1653.
35. Portoghese PS, Larson DL, Sayre LM, et al. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. J Med Chem. 1986;29.1855-1861.
36. Portoghese AS, Lipkowski AW, Takemori AE. Bimorphinans as highly selective, potent κ opioid receptor antagonists. J Med Chem. 1987;30:238-239.
37. Takemori AE, Portoghese PS. Selective naltrexone-derived opioid receptor antagonists, Annu Rev Pharmacol Toxicol. 1992;32:239-269.
38. Portoghese PS. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol Sci. 1989;10:230-235.
39. Schwyzer R. ACTH: a short introductory review. Ann N Y Acad Sci. 1977;297:3-26.
40. Lin C, Takemori AE, Portoghese PS, Synthesis and κ-opioid antagonist selectivity of a norbinaltorphimine congener. Identification of the address moiety reqired for κ-antagonist activity. J Med Chem. 1993;36:2412-2415.
41. Thomas JB, Atkinson RN, Vinson A, et al. Identification of (3R)-7-Hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3, 4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3- isoquinolinecarboxamide as a novel potent and selective opioid κ receptor antagonist. J Med Chem. 2003;46:3127-3137.
42. Grundt P, Williams IA, Lewis JW, Husbands SM. Identification of a new scaffold for κ opioid receptor antagonism based on the 2-amino-1,1-dimethyl-7-hydroxytetralin pharmacophore. J Med Chem. 2004;47:5069-5075.
43. Portoghese PS, Nagase H, Takemori AE. Only one pharmacophore is required for the κ opioid antagonist selectivity of norbinaltorphimine. J Med Chem. 1988;31:1344-1347.
44. Portoghese PS, Nagase H, Lipkowski AW, Larson DL, Takemori AE. Binaltorphimine-related bivalent ligands and their κ opioid receptor antagonist selectivity. J Med Chem. 1988;31:836-841.
45. Schmidhammer H, Ganglbauer E, Mitterdorfer J, Rollinger JM, Smith CFC. Synthesis and biological evaluation of 14-alkoxymorphinans 14,14′-dimethoxy analogues of norbinaltorphimine: synthesis and determination of their κ opioid antagonist selectivity. Helv Chim Acta. 1990;73:1779-1783.
46. Schmidhammer H, Smith CFC. A simple and efficient method for the preparation of binaltorphimine and derivatives and determination of their κ opioid antagonist selectivity. Helv Chim Acta. 1989; 72:675-677.
47. Portoghese PS, Garzon-Aburbeh A, Nagase H, Lin C, Takemori AE. Role of the spacer in conferring κ opioid receptor selectivity to bivalent ligands related to norbinaltorphimine. J Med Chem. 1991;34:1292-1296.
48. Portoghese PS, Lin C, Farouz-Grant R, Takemori AE. Structure-activity relationship of N17′substituted norbinaltorphimine congeners. Role of the N17′ basic group in the interaction with a putative address subsite on the κ opioid receptor. J Med Chem. 1994;37:1495-1500.
49. Thomas JB, Fix SE, Rothman RB, et al. Importance of phenolic address groups in opioid kappa receptor selective antagonists. J Med Chem. 2004;47:1070-1073.
50. Marki A, Otvos F, Toth G, Hosztafi S, Borsodi A. Tritiated kappa receptor antagonist norbinaltorphimine: synthesis and in vitro binding in three different tissues. Life Sci. 2000;66:43-49.
51. 2-alkylamidino) methyl]naltrindole derivatives as a novel class of κ opioid receptor antagonists. J Med Chem. 1993; 36:179-180.
52. Jones RM, Portoghese PS. 5′-Guanidinonaltrindole, a highly selective and potent κ-opioid receptor antagonist. Eur J Pharmacol, 2000;396:49-52.
53. Jales AR, Husbands SM, Lewis JW. Selective κ-opioid antagonists related to naltrindole. Effect of side-chain spacer in the 5′-amidinoalkyl series. Bioorg Med Chem Lett. 2000;10:2259-2261.
54. Black SL, Jales AR, Brandt W, Lewis JW, Husbands SM. The role of the side chain in determining relative δ- and κ-affinity in C5′-substituted analogues of naltrindole. J Med Chem. 2003; 46:314-317.
55. Black SL, Chauvignac C, Grundt P, et al. Guanidino N-substituted and N,N-disubstituted derivatives of the κ-opioid antagonist GNTI. J Med Chem. 2003;46:5505-5511.
56. Ananthan S, Kezar HS, Saini SK, et al. Synthesis, opioid receptor binding, and functional activity of 5′-subsitituted 17-cyclopropylmethylpyrido[2′,3′,:6,7]morphinans. Bioorg Med Chem Lett. 2003;13:529-532.
57. Thomas JB, Atkinson RN, Rothman RB, et al. Identification of the first trans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl) piperidine derivative to possess highly potent and selective opioid κ receptor antagonist activity. J Med Chem. 2001;44:2687-2690.
58. Zimmerman DM, Leander JD, Cantrell BE, et al. Structure-activity relationships of trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine antagonists for μ- and κ-opioid receptors. J Med Chem. 1993;36:2833-2841
59. Thomas JB, Fall MJ, Cooper JB, et al. Identification of an opioid κ receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine. J Med Chem. 1998;41:5188-5197.
60. Thomas JB, Atkinson RN, Namdev N, et al. Discovery of an opioid κ receptor selective pure antagonist from a library of N-substituted 4β-methyl-5-(3-hydroxyphenyl)morphans. J Med Chem. 2002; 45:3524-3530.
61. Grundt P, Williams IA, Lewis JW, Husbands SM. Identification of a new scaffold for opioid receptor antagonism based on the 2-amino-1, 1-dimethyl-7-hydroxytetralin pharmacophore, J Med Chem. 2004;47:5069-5075.
62. de Costa BR, Band L, Rothman RB, et al. Synthesis of an affinity ligand ('UPHIT') for in vivo acylation of the κ-opioid receptor, FEBS Lett. 1989;249:178-182.
63. de Costa BR, Rothman RB, Bykov V, Jacobson AE. Rice KC, Selective and enantiospecific acylation of κ opioid receptors by (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrrolidinyl)cyclohecyl] benzeneacetamide. Demonstration of κ receptor heterogeneity. J Med Chem. 1989;32:281-283.
64. Chang AC, Takemori AE, Portoghese PS. 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)- 2-(1-pyrrolidinyl)ethyl]acetamide: an opioid receptor affinity label that produces selective and long-lasting κ antagonism in mice. J Med Chem. 1994;37:1547-1549.
65. Chang AC, Takemori AE, Ojala WH, Gleason WB, Portoghese PS. κ opioid receptor selective affinity labels: electrophilic benzeneacetamides as κ-selective opioid antagonists. J Med Chem. 1994;37:4490-4498.
66. Chauvignac C, Miller CN, Srivastava SK, Lewis JW, Husbands SM, Traynor JR. Major effect of pyrrolic N-benzylation in norbinaltorphiminie, the selective κ-opioid receptor antagonist. J Med Chem. 2005; 48:1676-1679.
67. Negus SS, Mello NK, Linsenmayer DC, Jones RM, Portoghese PS. Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology (Berlin). 2002;163:412-419.
68. 2 analysis. J Pharmacol Exp Ther. 1987;243:591-597.
69. Negus SS, Butelman ER, Chang KJ, DeCosta B, Winger G, Woods JH. Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys. J Pharmacol Exp Ther. 1994;270:1025-1034.
70. Carroll I. Thomas JB, Dykstra LA, et al. Pharmacological properties of JDTic: a novel κ-opoid receptor antagonist. Eur J Pharmacol. 2004;501:111-119.
71. Butelman ER, Negus SS, Ai Y, deCosta BR, Woods JH. Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther. 1993;267:1269-1276.
72. Endoh T, Matsuura H, Tanaka C, Nagase H. Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther. 1992;316:30-42.
73. Broadbear JH, Negus SS, Butelman ER, de Costa BR, Woods JH. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacology (Berlin). 1994; 115:311-319.
74. Ko MCH, Lee H, Song MS, et al. Activation of κ-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther. 2003;305:173-179.
75. Jones DNC, Holtzman SG. Long term kappa opioid receptor blockade following nor-binaltorphimine. Eur J Pharmacol. 1992;215:345-348.
76. Horan P, Taylor J, Yamamura HI, Porreca F. Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther. 1992;260:1237-1243.
77. Ko MCH, Johnson MD, Butelman ER, Willmont KJ, Mosberg HI, Woods JH. Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys. J Pharmacol Exp Ther. 1999;291:1113-1120.
78. Jewett DC, Woods JH. Nor-binaltorphimine: a very, very long acting kappa opioid antagonist in pigeons. Behav Pharmacol 1995;6:815-820.
79. Takemori AE, Ho BY, Naeseth JS, Portoghese PS. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther. 1988;246:255-258.
80. Takemori AE, Schwartz MM, Portoghese PS. Suppression by nor-binaltorphimine of kappa opioid-mediated diuresis in rats. J Pharmacol Exp Ther. 1988;247:971-974.
81. Ko MCH, Willmont KJ, Lee H, Flory GS, Woods JH. Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys. Brain Res. 2003;982:38-44.
82. Carlezon WA Jr, Thome J, Olson VG, et al. Regulation of cocaine reward by CREB. Science. 1998;282:2272-2275.
83. Pliakas AM, Carlson RR, Neve RL, Konradi C, Nestler EJ, Carlexon WA. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J Neurosci. 2001;21:7397-7403.
84. McLaughlin JP, Marton-Popovici M, Chavkin C. κ opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci. 2003;23:5674-5683
85. Berrocoso E, Rojas-Corrales MO, Mico JA, Non-selective opioid receptor antagonism of the antidepressant-like effect of venlafaxine in the forced swimming test in mice. Neurosci Lett. 2004;363:25-28.
86. Newton SS, Thome J, Wallace TL, et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci. 2002;22:10883-10890.
87. Shirayama Y, Ishida H, Iwata M, Hazama G, Kawahara R, Duman RS. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem. 2004;90:1258-1268.
88. Kamei J, Nagase H. Norbinaltorphimine, a selective κ opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol. 2001;418:141-145.
89. Cowan A, Inan S, Kehner GB. GNTI, a kappa receptor antagonist, causes compulsive scratching in mice. The Pharmacologist. 2002;44:A51.
90. Togashi Y, Umeuchi H, Okano K, et al. Antipruritic activity of the κ-opioid receptor agonist, TRK-820. Eur J Pharmacol. 2002; 435:259-264.
91. Ko MCH, Lee H, Song MS, et al. Activation of κ-opioid receptors inhibits pruritus evoked by subcutaneous of intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther. 2003;305:173-179,
92. Umeuchi H, Togashi Y, Honda T, et al. Involvement of central μ-opioid system in the scratching behavior in mice, and the suppression of it by the activation of κ-opioid system. Eur J Pharmacol. 2003;477:29-35.
93. Levine AS, Grace M, Portoghese PS, Billington CJ. The effect of selective opioid antagonists on butorphanol-induced feeding. Brain Res. 1994;637:242-248.
94. Cole JL, Berman N, Bodnar RJ. Evaluation of chronic opioid receptor antagonist effects upon weight and intake measures in lean and obese zucker rats. Peptides. 1997;18:1201-1207.
95. Bodnar RJ, Glass MJ, Ragnauth A. Cooper ML. General, μ and κ opioid antagonists in the nucleus accumbens alter food intake under deprivation, glucoprivic and palatable conditions. Brain Res. 1995;700:205-212.
96. Leventhal L, Kirkham TC, Cole JL, Bodnar RJ. Selective actions of central μ and κ opioid antagonists upon sucrose intake in sham-fed rats. Brain Res. 1995;685:205-210.
97. Khaimova E, Kandov Y, Israel Y, Cataldo G, Hadjimarkou MM, Bodnar RJ. Opioid receptor subtype antagonists differentially alter GABA agonist-induced feeding elicited from either the nucleus accumbens shell or ventral tegmental area regions in rats. Brain Res. 2004;1026:284-294.
98. Kotz CM, Grace MK, Billington CJ, Levine AS. The effect of norbinaltorphimine, β-funaltrexamine and naltrindole on NPY-induced feeding. Brain Res. 1993:631:325-328.
99. Calcagnetti DJ, Calcagnetti RL, Fanselow MS. Centrally administered opioid antagonists, norbinaltorphimine, 16-methyl cyprenorphine, and Mr2266, suppress intake of a sweet solution. Pharmacol Biochem Behav. 1990;35:69-73.
100. Spanagel R, Shippenberg TS. Modulation of morphine-induced sensitization by endogenous κ opioid systems in the rat. Neurosci Lett. 1993; 153:232-236.
101. Williams KL, Ko MHC, Rice KC, Woods JH. Effect of opioid receptor antagonists on hypothalamic-pituitary-adrenal activity in rhesus monkeys. Psychoneuroendocrinology. 2003;28:513-528
102. Narita M, Kishimoto Y, Ise Y, Yajima Y, Misawa K, Suzuki T. Direct evidence for the involvement of the mesolimbic κ-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state. Neuropsychopharmacology. 2005;30:111-118.
103. Joynes RL, Grau JW. Instrumental learning within the spinal cord: III. Prior exposure to noncontingent shock induces a behavioral deficit that is blocked by an opioid antagonist. Neurobiol Learn Mem. 2004;82:35-51.
104. Cheng HY, Laviolette SR, van der Kooy D, Penninger JM. DREAM ablation selectively alters THC place aversion and analgesia but leaves intact the motivational and analgesic effects of morphine. Eur J Neurosci. 2004:19:3033-3041.
105. Mizoguchi H, Leitermann RJ, Narita M, Nagase H, Suzuki T, Tseng LF. Region-dependant G-protein activation by κ-opioid receptor agonists in the mouse brain. Neurosci Lett. 2004;356:145-147.
106. Fan L, Tien L, Tanaka S, et al. Enhanced binding of nor-binaltorphimine to κ-opioid receptors in rats dependent on butorphanol. J Neurosci Res. 2003;72:781-789.
107. Cosentino M, Marino F, DePonti F, et al. Tonic modulation of neurotransmitter release in the guinea-pig myenteric plexus: effect of μ and κ opioid receptor blockade and of chronic sympathetic denervation. Neurosci Lett. 1995;194:185-188.
108. Ossipov MH, Kovelowski CJ, Wheeler-Aceto H, at al. Opioid antagonists and antisera to endogenous opioids increase the nociceptive response to formalin: demonstration of an opioid kappa and delta inhibitory tone. J Pharmacol Exp Ther. 1996;277:784-788.
109. Obara I, Mika J. Schafer MK-H, Przewlocka B. Antagonists of the κ-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation. Br J Pharmacol. 2003;140:538-546.
110. Baker AK, Meert TF. Functional effects of systemically administered agonists and antagonists of μ, δ, and κ opioid receptor subtypes on body temperature in mice. J Pharmacol Exp Ther. 2002; 302:1253-1264.
111. Tortella FC, Echevarria E, Lipkowski AW, Takemori AE, Portoghese PS, Holaday JW. Selective kappa antagonist properties of nor-binaltrophimine in the rat seizure model. Life Sci. 1989;44:661-665.
112. Manzanares J, Lookingland KJ, LaVigne SD, Moore KE, Activation of tuberohypophysial dopamine neurons following intracerebroventricular administration of the selective kappa opioid receptor antagonist nor-binaltorphimine. Life Sci. 1991;48:1143-1149.
113. McIntosh M, Kane K, Parratt J. Effects of selective opioid receptor agonists and antagonists during myocardial ischaemia. Eur J Pharmacol. 1992;210:37-44.
114. Llobel F, Laorden ML. Effects of μ-, δ-, and κ-opioid antagonists in atrial preparations from failing human hearts. Gen Pharmacol. 1997;28:371-374.
115. ATP channels. Am J Physiol Heart Circ Physiol. 2003;285:H1032-H1039.
116. Carey GJ, Bergman J. Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists. J Pharmacol Exp Ther. 2001;297:215-223.
117. Jewett DC, Woods JH. Nor-binaltorphimine: an ultra-long acting kappa-opioid antagonist in pigeons. Behav Pharmacol. 1995;6:815-820.
118. Picker MJ, Mathewson C, Allen RM. Opioids and rate of positively reinforced behavior: III. Antagonism by the long-lasting kappa antagonist norbinaltorphimine. Behav Pharmacol. 1996;7:495-504.